Predicting Prognosis in Patients with Superficial Bladder Cancer

Ralph W deVere White, Eschelle Stapp

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Bladder cancer is the most common urologic malignancy and is expected to affect approximately 54,000 people in 1998. Superficial bladder tumors (Tis, Ta, and T1 lesions) account for approximately 70% to 80% of these malignancies. Although many advances have been made in the management of patients with superficial bladder cancer, such disease often recurs and can progress, leading to death. It is therefore imperative to find an accurate method of identifying patients at risk for disease progression. Many recent investigations have been conducted to determine whether new biological markers will help predict disease progression and, to a lesser extent, tumor response to treatment. These new markers include DNA ploidy, S-phase, certain monoclonal antibodies, the p53 (alias TP53) tumor-suppressor gene, the retinoblastoma (Rb) gene, cell adhesion molecules, and angiogenesis. It is hoped that such prognostic indicators, coupled with cytoscopic and pathologic characteristics of the tumor, will lead to selective aggressive treatment of patients at high risk for progression while sparing low-risk patients from unnecessary procedures.

Original languageEnglish (US)
Pages (from-to)1717-1723
Number of pages7
JournalOncology
Volume12
Issue number12
StatePublished - 1998
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Disease Progression
Neoplasms
Retinoblastoma Genes
Unnecessary Procedures
Ploidies
Cell Adhesion Molecules
Tumor Suppressor Genes
S Phase
Genetic Markers
Biomarkers
Monoclonal Antibodies
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Predicting Prognosis in Patients with Superficial Bladder Cancer. / deVere White, Ralph W; Stapp, Eschelle.

In: Oncology, Vol. 12, No. 12, 1998, p. 1717-1723.

Research output: Contribution to journalArticle

deVere White, Ralph W ; Stapp, Eschelle. / Predicting Prognosis in Patients with Superficial Bladder Cancer. In: Oncology. 1998 ; Vol. 12, No. 12. pp. 1717-1723.
@article{a780f4bdef594d9bb2fca6ba70184bf3,
title = "Predicting Prognosis in Patients with Superficial Bladder Cancer",
abstract = "Bladder cancer is the most common urologic malignancy and is expected to affect approximately 54,000 people in 1998. Superficial bladder tumors (Tis, Ta, and T1 lesions) account for approximately 70{\%} to 80{\%} of these malignancies. Although many advances have been made in the management of patients with superficial bladder cancer, such disease often recurs and can progress, leading to death. It is therefore imperative to find an accurate method of identifying patients at risk for disease progression. Many recent investigations have been conducted to determine whether new biological markers will help predict disease progression and, to a lesser extent, tumor response to treatment. These new markers include DNA ploidy, S-phase, certain monoclonal antibodies, the p53 (alias TP53) tumor-suppressor gene, the retinoblastoma (Rb) gene, cell adhesion molecules, and angiogenesis. It is hoped that such prognostic indicators, coupled with cytoscopic and pathologic characteristics of the tumor, will lead to selective aggressive treatment of patients at high risk for progression while sparing low-risk patients from unnecessary procedures.",
author = "{deVere White}, {Ralph W} and Eschelle Stapp",
year = "1998",
language = "English (US)",
volume = "12",
pages = "1717--1723",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "12",

}

TY - JOUR

T1 - Predicting Prognosis in Patients with Superficial Bladder Cancer

AU - deVere White, Ralph W

AU - Stapp, Eschelle

PY - 1998

Y1 - 1998

N2 - Bladder cancer is the most common urologic malignancy and is expected to affect approximately 54,000 people in 1998. Superficial bladder tumors (Tis, Ta, and T1 lesions) account for approximately 70% to 80% of these malignancies. Although many advances have been made in the management of patients with superficial bladder cancer, such disease often recurs and can progress, leading to death. It is therefore imperative to find an accurate method of identifying patients at risk for disease progression. Many recent investigations have been conducted to determine whether new biological markers will help predict disease progression and, to a lesser extent, tumor response to treatment. These new markers include DNA ploidy, S-phase, certain monoclonal antibodies, the p53 (alias TP53) tumor-suppressor gene, the retinoblastoma (Rb) gene, cell adhesion molecules, and angiogenesis. It is hoped that such prognostic indicators, coupled with cytoscopic and pathologic characteristics of the tumor, will lead to selective aggressive treatment of patients at high risk for progression while sparing low-risk patients from unnecessary procedures.

AB - Bladder cancer is the most common urologic malignancy and is expected to affect approximately 54,000 people in 1998. Superficial bladder tumors (Tis, Ta, and T1 lesions) account for approximately 70% to 80% of these malignancies. Although many advances have been made in the management of patients with superficial bladder cancer, such disease often recurs and can progress, leading to death. It is therefore imperative to find an accurate method of identifying patients at risk for disease progression. Many recent investigations have been conducted to determine whether new biological markers will help predict disease progression and, to a lesser extent, tumor response to treatment. These new markers include DNA ploidy, S-phase, certain monoclonal antibodies, the p53 (alias TP53) tumor-suppressor gene, the retinoblastoma (Rb) gene, cell adhesion molecules, and angiogenesis. It is hoped that such prognostic indicators, coupled with cytoscopic and pathologic characteristics of the tumor, will lead to selective aggressive treatment of patients at high risk for progression while sparing low-risk patients from unnecessary procedures.

UR - http://www.scopus.com/inward/record.url?scp=0005479569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0005479569&partnerID=8YFLogxK

M3 - Article

C2 - 9874845

AN - SCOPUS:0005479569

VL - 12

SP - 1717

EP - 1723

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 12

ER -